Synthetic Biologics, Inc.

82 articles about Synthetic Biologics, Inc.

• Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma

  9/30/2022

  Synthetic Biologics, Inc. today announced the presentation of new data from collaborators at Fundació Sant Joan de Déu that further support evaluation of VCN-01, an oncolytic adenovirus expressing hyaluronidase, and topotecan for the treatment of refractory retinoblastoma.

• Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

  9/27/2022

  Synthetic Biologics, Inc. today announced a positive outcome from the Data and Safety Monitoring Committee (DSMC) review of results from the first Cohort of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

• Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  9/5/2022

  Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced a presentation of initial data from a Phase 1 investigator-sponsored study evaluating VCN-01 in combination with durvalumab for patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

• Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

  8/11/2022

  Synthetic Biologics, Inc today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

• Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

  8/4/2022

  Synthetic Biologics, Inc. announced that Company’s management will participate in one-on-one investor meetings at the BTIG Biotechnology Conference 2022, to be held virtually and in New York City from August 8-9, 2022.

• Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results

  8/4/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Thursday, August 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a corporate update.

• Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock - July 29, 2022

  7/29/2022

  Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced the private placement of 275,000 shares of Series C convertible preferred stock and 100,000 shares of Series D convertible preferred stock.

• Synthetic Biologics Announces Reverse Stock Split - July 15, 2022

  7/15/2022

  Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one share of common stock for every ten shares of common stock, effective as of 12:01 a.m. on July 25, 2022.

• Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results

  5/16/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the year ended March 31, 2022, and provided a corporate update.

• 

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  5/16/2022

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.

• Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

  5/10/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP).

• Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

  5/9/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update.

• Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

  5/5/2022

  Synthetic Biologics, Inc. announced the strengthening of its oncology leadership team with the formation of a Scientific Advisory Board composed of key opinion leaders in oncolytic viruses and gene therapies.

• Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

  5/4/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), today announced an upcoming oral presentation on novel oncolytic adenovirus VCN-11 at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually and in-person from May 16-19, 2022 in Washington, D.C.

• 

  New Therapies Bring Meaningful Life Extension to Pancreatic Cancer Patients

  4/6/2022

  Speakers at the 2022 Virtual Growth Conference’s session on pancreatic cancer acknowledged the exceptional challenges while extolling advances in immune-based therapies and combination approaches.

• Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors

  3/28/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), today announced the peer-reviewed publication of a Phase 1, multicenter, open-label, dose-escalation study investigating the therapeutic potential of intravenous VCN-01 oncolytic adenovirus with or without standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) in patients with advanced solid tumors.

• Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation

  3/23/2022

  Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced that Frank Tufaro, Ph.D., will transition from Chief Operating Officer of recently acquired VCN Biosciences to Chief Operating Officer of Synthetic Biologics.

• Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference

  3/22/2022

  Synthetic Biologics, Inc. announced that Company’s Management will provide a corporate update and participate in a panel discussion entitled “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim 2022 Virtual Growth Conference, to be held virtually March 28-March 30, 2022.

• Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results

  3/16/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the year ended December 31, 2021, and provided a corporate update.

• Synthetic Biologics Completes Acquisition of VCN Biosciences

  3/11/2022

  Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions.